Clinical trial · Observational
Comparison of the Complications in Multiple Myeloma Patients Who Received Autologous Stem Cell Transplantation Between in HEPA-filtered Room and Non-HEPA-filtered Room
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this observational study is to comparison of the complications in multiple myeloma patients who received autologous stem cell transplantation between in HEPA-filtered room and non-HEPA-filtered room. The main questions it aims to answer are: * The incidence of febrile neutropenia, infection, and duration of hospital stay * 2-year progression free survival Participants will be collected the data of baseline diagnosis, treatment, treatment results and complications during admission and follow-up visits from hospital medical record.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- HEPA-filtered room
- description
- multiple myeloma patients who received autologous stem cell transplantation were admitted in HEPA-filtered room
- label
- non-HEPA-filtered room
- description
- multiple myeloma patients who received autologous stem cell transplantation were admitted in non-HEPA-filtered room
Primary outcomes (4)
- measure
- febrile neutropenia
- timeFrame
- during admission
- description
- incidence of febrile neutropenia
- measure
- Infection
- timeFrame
- during admission
- description
- incidence of Infection
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * aged 18 - 65 years old * Patients with multiple myeloma undergoing treatment with autologous stem cell transplantation and having a Hematopoietic Cell Transplantation-Specific Comorbidity Index (HCT-CI) score less than or equal to 2 * Patients must provide signed consent to participate in the research if they undergo ASCT after the study has been approved. * If patients undergo ASCT before the study approval, retrospective data will be collected. Exclusion Criteria: * Patients with concomitant other types of cancer * Patients who refuse to participate in the study.
References
Publications (0)
Data not yet available